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Abstract. Background. Non-alcoholic fatty liver disease (NAFLD), an independent nosological entity, is cha-
racterized by fat accumulation in hepatocytes not associated with alcohol abuse, and includes a wide spectrum 
of disorders: from fatty liver, non-alcoholic steatohepatitis to fibrosis with possible outcome in liver cirrhosis. 
Given the prevalence of this disease, the deterioration of the quality of life of patients, increased mortality from 
complications, there is a growing interest in developing techniques for accurate and timely assessment of fibro-
sis. Objective: comparative characteristics of the results of transient elastometry (FibroScan) and non-invasive 
laboratory indices in the determination of fibrotic transformation of the liver in patients with non-alcoholic fatty 
liver disease. Materials and methods. The study included patients with NAFLD, who underwent diagnostics 
and treatment in the department of liver and pancreas of the SI “Institute of Gastroenterology of the NAMS 
of Ukraine”. Results. We have examined 42 patients with NAFLD, among which 18 (45 %) men and 24 (55 %) 
women. All patients underwent calculation of non-invasive markers of liver fibrosis: aspartate aminotransferase 
to platelet ratio index (APRI), fibrosis-4 index, aspartate aminotransferase/alanine aminotransferase ratio, the 
measurement of liver stiffness using the FibroScan apparatus. Conclusions. Our results are consistent with 
most studies indicating that the most effective non-invasive index is APRI. The combination of transient elasto-
graphy (FibroScan) and the APRI may provide a more effective approach to the diagnosis of liver fibrosis 
in patients with NAFLD.
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Introduction
Non-alcoholic fatty liver disease is a condition of excess 
fat in the hepatic parenchyma in the absence of significant 
alcohol consumption. The boundary value is 5 % fatty in-
clusions according to the morphological study, or 5.6 % 
according to the results of magnetic resonance spectros-
copy [1]. NAFLD is a worldwide problem with prevalence 
according to various studies from 12.5 to 51 %. The scope 
of these indicators is due to the presence of various risk fac-
tors and depends on the methods of diagnosis [1–4]. The 
spectrum of pathology included in the concept of NAFLD 
consists of simple steatosis, steatohepatitis with the possibi-
lity of progression to cirrhosis of the liver and even hepa-
tocellular carcinoma. Recently, there is an understanding 
that NAFLD is a hepatic embodiment of the metabolic 
syndrome and is closely related to insulin resistance, the 
risk of cardiovascular pathology and the development of di-
abetes mellitus. Rapid progression of fibrosis is a significant 
problem, although it occurs in a small number of patients 
with fatty disease. A gold standard for isolating a group of 
patients at risk of disease progression and to determine the 
degree of fibrosis is still considered a morphological study, 
although liver biopsy is associated with certain inconve-
niences and life-threatening complications [5].
In the last decade, alternative methods of non-invasive 
or minimally invasive determination of the degree of fibrosis 
with various liver pathologies, including NAFLD, are ac-
tively developing. Among them, the evaluation of various 
indices calculated on the basis of blood values — the ratio 
of activity of aspartate aminotransferase (AST) to the num-
ber of platelets (APRI), the ratio of aspartate aminotrans-
ferase to alanine aminotransferase (AST/ALT), commercial 
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Table 1 — Platelet and hepatic enzyme 
indices in the examined patients
Lab. test M ± SD Normal range
Platelets, g/l 252.47 ± 66.82 150–450
Serum АLТ, U/l 68.54 ± 56.81 ≤ 40
Serum АSТ, U/l 46.98 ± 32.74 ≤ 40
integral indices — NAFLD fibrosis score (NFS), Fibrosis 4 
calculator (FIB-4) [1]. In the diagnosis of NAFLD, imaging 
me thods are becoming increasingly important. Ultrasound, 
computer and magnetic resonance imaging, magnetic re-
sonance spectroscopy, and transient elastography are used. 
Computed tomography is used in a limited way because of 
both the radiation load and lack of sensitivity.
Transient elastography (TE) measures the propagation 
velocity of transverse waves at a depth of 25–65 mm and is 
converted to a liver stiffness measurement (LSM). The re-
sistance of deformation, which depends on the rigidity of 
the liver, is expressed by the Young’s modulus in kilopascals 
(kPa). The TE uses the formula E = 3pV2, which is based on 
Hooke’s law, where E is Young’s modulus, p is the density 
(presu mably 1000 kg/m3) and V is the velocity of propaga-
tion of transverse waves [6].
The advantages of TE are simplicity, non-invasiveness, 
as well as high clinical significance. Restrictions on the use 
of the method are the presence of ascites in the patient, ex-
cessively developed fatty tissue, narrow intercostal spaces. 
The effectiveness of TE in patients with viral hepatitis has al-
ready been confirmed by a large number of studies [7, 8]. At 
the same time, the diagnostic capabilities of the method in 
patients with NAFLD have not been adequately described.
The purpose. Comparative characteristics of the results 
of transient elastometry (FibroScan) and non-invasive labo-
ratory indices in the determination of fibrous liver transfor-
mation in patients with NAFLD.
Materials and methods
The study included patients with NAFLD who underwent 
examination and treatment in the Department of Liver and 
Pancreatic Diseases at the Institute of Gastroenterology of the 
National Academy of Medical Sciences of Ukraine. The diag-
nosis was based on ultrasound examination of the abdominal 
organs and evaluation of the activity of liver enzymes. Patients 
with different liver diseases, including viral, drug, autoim-
mune and alcoholic hepatitis, were excluded from the study.
The activity of ALT and AST in blood serum was de-
termined by the colorimetric dinitrophenylhydrazine 
Reitman-Frankel method. The laboratory reference range 
of ALT and AST was up to 40 U/l, and the normal platelet 
count was 150–450 g/l.
The LSM was performed on a FibroScan 502 Touch 
F 60156 machine, by the company Echosens (France). 
The impact of the sensor pin was applied to the right in-
tercostal space at the level of the anterior or middle ax-
illary line and was directed to the right lobe of the liver. 
Using ultrasonic M- and A-mode, the shear wave propa-
gation velocity and the controlled ultrasonic attenuation 
parameter were estimated through a standard 4 cm sec-
tion. The final result was expressed in kPa and was the 
median value of 10 individual actual measurements. The 
studies, which resulted in 10 valid measurements with a 
valid level of at least 60 % and an interquartile range of no 
more than 30 % of the median stiffness values, were con-
sidered successful. The results were evaluated as follows: 
F0 — 0–5.9 kPa, F1 — 6–6.9 kPa, F2 — 7–9 kPa, 
F3 — 9.1–10.3 kPa, F4 — 10.4 kPa and more.
The AST/ALT ratio was calculated for each patient.
APRI was calculated by dividing the AST level [U/l], 
expressed as the number of times above the upper limit of 
normal [ULN], by platelet count [g/l]: 
APRI = (AST [U⁄l] × 100) ⁄ (AST [ULN] × 
× platelet count [g⁄l]).
FIB-4 was calculated using the formula: 
FIB-4 = (age [years] × AST [U/l]) / (platelet count [g/l] × 
× √ALT [U/l]).
The statistical analysis was carried out with the Statis-
tica for Windows 6.0. Since most of the data had a normal 
distribution, parametric statistics were used — mean (M) 
and standard deviation (SD). Correlation analysis was 
used to reveal the interrelations between different values of 
the investigated indicators. To determine the significance 
of the differences between the integral indices of fibrosis 
(AST/ALT, APRI and FIB-4) in patients with minimal 
(F0–1), moderate (F2–3) and severe (F4) fibrosis, the Stu-
dent’s t-test was applied. The difference was considered sig-
nificant when p < 0.05.
Results
42 patients with NAFLD were examined, including 
18 (45 %) men and 24 (55 %) women; the average age of 
patients was 44.9 ± 1.6 years.
There were no significant differences in age, platelet 
count, ALT and AST activity between men and women. The 
results of a biochemical blood test and platelet count are 
shown in Table 1.
The average liver stiffness index was (9.10 ± 1.33) kPa 
and in most patients there was no fibrosis (F0 — 31 %) or fi-
brosis was moderately expressed (F1/2 — 45.3 %) (Table 2). 
In male patients, the stiffness index was higher than in wom-
en, but this difference was not significant (11.7 (SD: 12.7) 
compared with 7.1 (SD: 2.22), respectively, p = 0.091). Ac-
cording to TE, the patients were divided into 3 groups: 1 — 
with minimal fibrosis (F0–1), 2 — with moderate fibrosis 
(F2–3) and 3 — with severe liver fibrosis.
Correlation analysis revealed a positive relationship be-
tween ALT level and liver stiffness (r = 0.32 and 0.47 for 
p = 0.003 and 0.002 for Kendall and Spearman correlations, 
respectively), as well as AST level and liver stiffness (r = 0.39 
and 0.55 at p = 0.0002 and 0.0001 for Kendall and Spearman 
correlations, respectively). There was also a positive corre-
lation between APRI and transient elastometry (r = 0.33 
and 0.49 for p = 0.002 and 0.001 for Kendall and Spearman 
correlations, respectively). There was a significant diffe-
rence in the APRI score between patients with moderate to 
Том 51, № 3, 2017 185www.gastro.org.ua, http://gastro.zaslavsky.com.ua
Патологія печінки і жовчовивідної системи / Pathology of Liver and Biliary Excretion System
Table 2 — Distribution of different degrees 
of fibrosis in the examined patients according 
to transient elastometry
The stage of fibrosis (kPa) N (%)
F0 (≤ 5.9) 13 (31)
F1 (6–6.9) 7 (16.7)
F2 (7.0–9.0) 12 (28.6)
F3 (9.1–10.3) 3 (7)
F4 (≥ 10.4) 7 (16.7)
All patients 42 (100)
Tablе 3 — Integral indicators of liver fibrosis 
and the reliability of differences between them 








LSM, kPa 5.13 ± 1.36* 8.30 ± 0.82* 22.14 ± 15.96
FIB-4 0.98 ± 0.69 1.08 ± 0.33 1.60 ± 1.10
APRI 0.37 ± 0.24 0.44 ± 0.21* 0.998 ± 0.550
АSТ/АLТ 0.78 ± 0.28 0.71 ± 0.20 0.96 ± 0.45
Note. * — р < 0.001.
severe (F2–3/F4), and initial and severe (F0–1/F4) fibrosis 
(Table 3).
A weak correlation between FibroScan, APRI, FIB-4 
and AST/ALT ratio (Fig. 1–3) can be explained by the small 
number of patients examined, which necessitates continua-
tion of this study, as well as further monitoring of patients at 
the stages of NAFLD development.
Discussion
The pathophysiology of a specific disease lies at the 
heart of the development of biomarkers, reflecting the dif-
ferent stages of the development of this disease. In the case 
of NAFLD, there are two potential targets for resear chers. 
The first is the introduction of markers in practice, by 
which one could distinguish simple steatosis from steato-
hepatitis — a state with a more serious prognosis. The se-
cond goal is to identify the stage of fibrosis. Most prospec-
tive cohort studies of patients with NAFLD showed that the 
prognosis is determined by the stage and level of progres-
sion of fibrosis even more than by the presence of necrotic 
inflammation. Clinical significance is the possibility of dif-
ferentiation between absence or minimal fibrosis (F0–1), 
significant fibrosis (F2), severe fibrosis (F3) and cirrhosis 
(F4) [9].
F.C. Kruger, C.R. Daniels, M. Kidd and colleagues eval-
uated the results of 111 patients with histologically proven 
fatty liver disease. Biopsy specimens were described accord-
ing to the NASH clinical research network criteria. Groups 
with steatosis, steatohepatitis with absent or moderate fibro-
sis and with severe fibrosis were identified. The sensitivity 
and specificity of APRI with NFS and ALT/AST ratio were 
compared. The APRI value was significantly higher with se-
Figure 1 — Correlation between the FibroScan 
(liver stiffness, kPa) and the AST/ALT ratio
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Figure 2 — Correlation between the FibroScan 
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vere fibrosis. So the optimal cut-off point was 0.98 with a 
sensitivity of 75 % and a specificity of 86 %. The NFS for 
steatohepatitis was significantly lower in the group with se-
vere fibrosis. Positive predictive value was 54 % for APRI, 
while for NFS it was 34 %. The negative predictive value 
was 93 % for APRI and 94 % for NFS. Analysis of the data 
showed that for the diagnosis of severe fibrosis APRI is more 
preferable than NFS and ALT/AST [10].
A group of American scientists retrospectively analyzed 
a database of 514 adult patients with NAFLD, assessing the 
diagnostic accuracy of FIB-4, comparing it with seven other 
non-invasive markers. The authors concluded that FIB-4 is 
superior to other fibrosis indices in patients with NAFLD, 
but there is still a need to develop more sensitive non-inva-
sive markers [11].
English scientists S. McPherson, S.F. Stewart, E. Hender-
son et al. compared morphology data of 145 Newcastle 
Hospitals Fatty Liver Clinic patients over a 6-year pe-
riod. The FIB-4 scale had the best diagnostic accuracy 
for severe fibrosis — AUROC = 0.86, the AST/ALT ratio 
(AUROC = 0.83), NFS (AUROC = 0.81), and the AST/
platelet ratio (AUROC = 0.67). AST/ALT, FIB-4 and NFS 
had a negative predictive value above 90 %. The positive prog-
nostic value was moderate. To exclude severe hepatic fibrosis, 
biopsies can potentially be avoided in 69 % of patients with 
AST/ALT, 62 % with FIB-4, 52 % with NFS [12].
The French P. Calès, F. Lainé, J. Boursier compared 
the NAFLD-specific certified FibroMeter and NFS tests 
with the non-specific APRI test. The data of 235 patients 
with fatty liver disease of two clinical centers were evalu-
ated. The highest accuracy was 91 % with a marked fibrosis 
in FibroMeter, whose AUROC was 0.94, which was signifi-
cantly higher than in NFS (0.884, p = 0.008) and APRI 
(0.866, p < 0.001). Using threshold values of 90% predic-
tive value, liver biopsy could be avoided in most patients: 
FibroMeter — 97.4 %, NFS: 86.8 % (p < 0.001) and APRI: 
80.0% (p < 0.001) [13].
Conclusions
In our study, the standard with which we compared the 
minimally invasive markers of fibrosis was transient elas-
tometry. According to the results of many years of clinical 
practice, TE measurement by FibroScan is a safe method 
allowing to determine the degree of fibrosis with high ac-
curacy. The results of our work are consistent with most 
studies, according to which the most effective of minimally 
invasive indices is APRI. With its help, it is possible to diffe-
rentiate the stage of fibrosis with high accuracy (from mode-
rate — F2–3 to severe F4), but its use is limited in the diag-
nosis of initial fibrosis (F1). The combination of transient 
elastometry (FibroScan) and the APRI can provide a more 
efficient approach in the diagnosis of liver fibrosis in patients 
with NAFLD. Thus, the use of TE with FibroScan in com-
bination with the APRI allows early diagnosis of fibrosis as 
an alternative to puncture liver biopsy.
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FibroScan і неінвазивні індекси 
в діагностиці неалкогольної жирової хвороби печінки
Резюме. Актуальність. Неалкогольна жирова хвороба печін-
ки (НАЖХП) є самостійною нозологічною одиницею, харак-
теризується накопиченням жиру в гепатоцитах, не пов’язаним 
зі зловживанням алкоголем, і включає широкий спектр пору-
шень — від жирової дистрофії печінки, неалкогольного стеа-
тогепатиту до фіброзу з можливим переходом у цироз печін-
ки. З огляду на поширеність цієї патології, погіршення якості 
життя хворих, збільшення смертності від ускладнень зростає 
інтерес до розробки методів для точної й своєчасної оцінки 
фіброзу. Мета: порівняльна характеристика результатів тран-
зієнтної еластометрії (FibroScan) і неінвазивних лабораторних 
індексів у визначенні фіброзної трансформації печінки у хво-
рих із неалкогольною жировою хворобою печінки. Матеріали 
та методи. У дослідження включені пацієнти з НАЖХП, які 
проходили обстеження й лікування у відділенні захворювань 
печінки та підшлункової залози ДУ «Інститут гастроентероло-
гії НАМН України». Обстежені 42 пацієнти з НАЖХП, серед 
яких 18 (45 %) чоловіків і 24 (55 %) жінки. Усім пацієнтам було 
виконано розрахунок неінвазивних маркерів фіброзу печінки: 
APRI, FIB-4, співвідношення аланінамінотрансферази/ас-
партатамінотрансферази, проведено вимірювання жорсткості 
печінки за допомогою апарату FibroScan. Результати нашої 
роботи узгоджуються з більшістю досліджень, згідно з яки-
ми найбільш ефективним з малоінвазивних індексів є APRI. 
Висновки. Поєднання транзієнтної еластометрії (FibroScan) 
з індексом APRI може забезпечити більш ефективний підхід 
до діагностики фіброзу печінки у хворих з НАЖХП.
Ключові слова: неалкогольна жирова хвороба печінки; фі-
броз печінки; неінвазивні методи діагностики; транзієнтна 
еластометрія 
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FibroScan и неинвазивные индексы 
в диагностике неалкогольной жировой болезни печени
Резюме. Актуальность. Неалкогольная жировая болезнь 
печени (НАЖБП) является самостоятельной нозологиче-
ской единицей, характеризуется накоплением жира в ге-
патоцитах, не связанным со злоупотреблением алкоголем, 
и включает широкий спектр нарушений — от жировой ди-
строфии печени, неалкогольного стеатогепатита до фиброза 
с возможным исходом в цирроз печени. С учетом распро-
страненности этой патологии, ухудшения качества жизни 
больных, увеличения смертности от осложнений растет 
интерес к разработке методов для точной и своевременной 
оценки фиброза. Цель: сравнительная характеристика ре-
зультатов транзиентной эластометрии (FibroScan) и неин-
вазивных лабораторных индексов в определении фиброзной 
трансформации печени у больных с НАЖБП. Материалы 
и методы. В исследование включены пациенты с НАЖБП, 
которые проходили обследование и лечение в отделении за-
болеваний печени и поджелудочной железы ГУ «Институт 
гастроэнтерологии НАМН Украины». Обследовано 42 паци-
ента с НАЖБП, среди которых 18 (45 %) мужчин и 24 (55 %) 
женщины. Всем пациентам был выполнен расчет неинва-
зивных маркеров фиброза печени: APRI, FIB-4, соотноше-
ние аланинаминотрансферазы/аспартатаминотрансферазы, 
проведено измерение жесткости печени при помощи ап-
парата FibroScan. Результаты нашей работы согласуются 
с большинством исследований, согласно которым наиболее 
эффективным из малоинвазивных индексов является APRI. 
Выводы. Сочетание транзиентной эластометрии (FibroScan) 
с индексом APRI может обеспечить более эффективный под-
ход к диагностике фиброза печени у больных с НАЖБП.
Ключевые слова: неалкогольная жировая болезнь печени; 
фиброз печени; неинвазивные методы диагностики; транзи-
ентная эластография
